Halozyme Therapeutics, Inc. (HALO) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $125.63 +0.88%
Revenue Growth %: +37.6%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +37.6%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $5.63 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Accenture shares fall on insider sales and analyst downgrade
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
